# A BILL FOR AN ACT

RELATING TO CONTROLLED SUBSTANCES.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

```
1
                      Section 329-14, Hawaii Revised Statutes, is
         SECTION 1.
2
    amended by amending subsection (d) to read as follows:
3
               Any material, compound, mixture, or preparation that
         " (d)
4
    contains any quantity of the following hallucinogenic
5
    substances, their salts, isomers, and salts of isomers, unless
6
    specifically excepted, whenever the existence of these salts,
7
    isomers, and salts of isomers is possible within the specific
8
    chemical designation:
9
              Alpha-ethyltryptamine (AET);
         (1)
10
         (2)
              2,5-dimethoxy-4-ethylamphetamine (DOET);
11
         (3)
              2,5-dimethoxyamphetamine (2,5-DMA);
12
         (4)
              3,4-methylenedioxy amphetamine;
13
              3,4-methylenedioxymethamphetamine (MDMA);
         (5)
14
              N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
         (6)
15
              MDA);
16
         (7)
              3,4-methylenedioxy-N-ethylamphetamine (MDE);
17
              5-methoxy-3,4-methylenedioxy-amphetamine;
         (8)
18
              4-bromo-2,5-dimethoxy-amphetamine(4-bromo-2,5-DMA);
    HB2592 HD1 HMS 2010-1809
```

```
1
        (10)
               4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
 2
        (11)
               3,4,5-trimethoxy amphetamine;
 3
               Bufotenine;
         (12)
 4
               4-methoxyamphetamine (PMA);
         (13)
 5
               Diethyltryptamine;
        (14)
 6
        (15)
               Dimethyltryptamine;
7
        (16)
               4-methyl-2,5-dimethoxy-amphetamine;
8
        (17)
               Gamma hydroxybutyrate (GHB) (some other names include
9
               gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
10
               hydroxybutanoic acid; sodium oxybate; sodium
11
               oxybutyrate);
12
        (18)
               Ibogaine;
13
               Lysergic acid diethylamide;
        (19)
14
        (20)
               Marijuana;
15
        (21)
               Parahexyl;
16
        (22)
               Mescaline;
17
        (23)
               Peyote;
18
        (24)
               N-ethyl-3-piperidyl benzilate;
19
               N-methyl-3-piperidyl benzilate;
        (25)
20
               Psilocybin;
        (26)
21
        (27)
               Psilocyn;
22
        (28)
               1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
```

```
1
              Tetrahydrocannabinols;
        (29)
2
        (30)
              Ethylamine analog of phencyclidine (PCE);
3
              Pyrrolidine analog of phencyclidine (PCPy, PHP);
        (31)
4
        (32)
              Thiophene analog of phencyclidine (TPCP; TCP);
5
              Gamma-butyrolactone, including butyrolactone;
        (33)
6
              butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
7
              dihydro; dihydro-2(3H)-furanone; tetrahydro-2-
8
              furanone; 1,2-butanolide; 1,4-butanolide; 4-
9
              butanolide; gamma-hydroxybutyric acid lactone; 3-
10
              hydroxybutyric acid lactone and 4-hydroxybutanoic acid
11
              lactone with Chemical Abstract Service number 96-48-0
12
              when any such substance is intended for human
13
              ingestion;
14
        (34)
              1,4 butanediol, including butanediol; butane-1,4-diol;
15
              1,4- butylenes glycol; butylene glycol; 1,4-
16
              dihydroxybutane; 1,4- tetramethylene glycol;
17
              tetramethylene glycol; tetramethylene 1,4- diol with
18
              Chemical Abstract Service number 110-63-4 when any
19
              such substance is intended for human ingestion;
20
              2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
        (35)
21
              its optical isomers, salts, and salts of isomers;
```

```
1
        (36)
              N-benzylpiperazine (BZP; 1-benzylpiperazine) its
 2
               optical isomers, salts, and salts of isomers;
 3
              1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
        (37)
 4
              optical isomers, salts, and salts of isomers;
 5
              Alpha-methyltryptamine (AMT), its isomers, salts, and
        (38)
 6
              salts of isomers; [and]
 7
        (39)
              5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT), its
               isomers, salts, and salts of isomers [-];
 8
 9
        (40)
              Salvia divinorum;
10
        (41)
              Salvinorin A; and
11
              Divinorin A."
        (42)
         SECTION 2. Section 329-16, Hawaii Revised Statutes, is
12
13
    amended by amending subsection (c) to read as follows:
               Any of the following opiates, including their
14
         "(c)
15
    isomers, esters, ethers, salts, and salts of isomers, whenever
16
    the existence of these isomers, esters, ethers, and salts is
17
    possible within the specific chemical designation:
18
         (1)
              Alfentanil;
19
         (2)
             Alphaprodine;
20
         (3)
             Anileridine;
21
         (4)
             Bezitramide;
22
              Bulk Dextropropoxyphene (nondosage form);
```

```
1
         (6)
               Carfentanil;
2
         (7)
              Dihydrocodeine;
3
         (8)
              Diphenoxylate;
4
         (9)
               Fentanyl;
5
               Isomethadone;
        (10)
6
               Levo-alphacetylmethadol (LAAM);
        (11)
7
        (12)
              Levomethorphan;
8
              Levorphanol;
        (13)
9
        (14)
              Metazocine:
10
        (15)
              Methadone:
11
              Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-
        (16)
12
               diphenyl butane;
13
        (17)
              Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-
14
               diphenyl-propane-carboxylic acid;
15
              Pethidine (Meperidine);
        (18)
16
              Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
        (19)
17
              phenylpiperidine;
18
              Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
        (20)
19
              carboxylate;
20
              Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-
        (21)
21
               4-carboxylic acid;
22
              Phenazocine:
        (22)
```

```
1
        (23)
              Piminodine;
 2
              Racemethorphan;
        (24)
 3
              Racemorphan;
        (25)
 4
        (26)
              Remifentanil; [and]
 5
        (27)
              Sufentanil [-]; and
 6
        (28)
              Tapentadol."
         SECTION 3. Section 329-20, Hawaii Revised Statutes, is
7
8
    amended by amending subsection (b) to read as follows:
9
               Depressants. Any material, compound, mixture, or
10
    preparation which contains any quantity of the following
11
    substances, including its salts, isomers, esters, ethers, and
12
    salts of isomers, whenever the existence of these isomers,
13
    esters, ethers, and salts is possible within the specific
14
    chemical designation, that has a degree of danger or probable
15
    danger associated with a depressant effect on the central
16
    nervous system:
17
         (1)
              Alprazolam;
18
         (2)
              Barbital;
19
         (3)
              Bromazepam;
20
         (4)
              Butorphanol;
21
         (5)
              Camazepam;
22
         (6)
              Carisoprodol;
```

```
1
          (7)
                Chloral betaine;
 2
           (8)
                Chloral hydrate;
 3
          (9)
                Chlordiazepoxide;
 4
         (10)
                Clobazam;
 5
                Clonazepam;
         (11)
 6
         (12)
                Clorazepate;
 7
         (13)
                Clotiazepam;
 8
         (14)
                Cloxazolam;
 9
         (15)
                Delorazepam;
10
         (16)
                Dichloralphenazone (Midrin);
11
         (17)
               Diazepam;
12
         (18)
                Estazolam;
13
         (19)
                Ethchlorvynol;
14
         (20)
                Ethinamate;
15
         (21)
               Ethyl loflazepate;
16
               Fludiazepam;
         (22)
17
         (23)
               Flunitrazepam;
18
         (24)
               Flurazepam;
19
         (25)
               Fospropofol (Lusedra);
20
        \left[\frac{(25)}{}\right] (26) Halazepam;
21
        [\frac{(26)}{(27)}] (27) Haloxazolam;
22
        [\frac{(27)}{}] (28)
                      Ketazolam;
```

```
1
          [\frac{(28)}{(29)}]
                            Loprazolam;
 2
          [<del>(29)</del>] (30)
                            Lorazepam;
 3
          [<del>(30)</del>] (31) Lormetazepam;
 4
          [\frac{(31)}{}] (32)
                            Mebutamate;
 5
          [\frac{(32)}{(33)}]
                            Medazepam;
 6
          [<del>(33)</del>] (34)
                            Meprobamate;
 7
          [<del>(34)</del>] (35) Methohexital;
 8
          [<del>(35)</del>] (36)
                            Methylphenobarbital (mephorbarbital);
 9
          [<del>(36)</del>] <u>(37)</u>
                            Midazolam;
10
          [\frac{(37)}{}] (38)
                            Nimetazepam;
11
          [<del>(38)</del>] (39)
                            Nitrazepam;
12
          [\frac{(39)}{(40)}]
                            Nordiazepam;
13
          [\frac{(40)}{(41)}]
                            Oxazepam;
14
          \left[\frac{(41)}{(42)}\right] (42) Oxazolam;
15
          [\frac{(42)}{(43)}]
                          Paraldehyde;
16
          [<del>(43)</del>] (44) Petrichloral;
17
          [-(44)] (45)
                          Phenobarbital;
18
          [-(45)] (46) Pinazepam;
19
          [\frac{(46)}{(47)}]
                            Prazepam;
20
          [<del>(47)</del>] (48)
                           Quazepam;
21
          [\frac{(48)}{(49)}]
                            Temazepam;
22
          [\frac{(49)}{(50)}]
                            Tetrazepam;
     HB2592 HD1 HMS 2010-1809
```

```
1
        [<del>(50)</del>] (51) Triazolam;
 2
        \left[\frac{(51)}{(52)}\right] (52) Zaleplon;
        [<del>(52)</del>] (53) Zolpidem; and
 4
        [<del>(53)</del>] (54) Zopiclone (Lunesta)."
5
        SECTION 4. Section 329-22, Hawaii Revised Statutes, is
6
    amended by amending subsection (d) to read as follows:
7
          " (d)
                Depressants. Unless specifically exempted or
    excluded or unless listed in another schedule, any material,
8
9
    compound, mixture, or preparation that contains any quantity of
10
    the following substances having a depressant effect on the
11
    central nervous system, including its salts, isomers, and salts
12
    of isomers:
13
         (1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
14
               propionamide], (Vimpat); and
15
         [\frac{1}{1}] (2) Pregabalin [S] -3-[A] (aminomethyl)-5-methylhexanoic
16
               acidl."
17
         SECTION 5. Section 329-35, Hawaii Revised Statutes, is
18
    amended to read as follows:
19
          "§329-35 Order to show cause. (a) [Before denying,
20
    suspending, or revoking a registration, or refusing a renewal of
    registration, the department of public safety shall-serve upon
21
22
    the applicant or registrant an order to show cause why
    HB2592 HD1 HMS 2010-1809
```

1 registration should not be denied, revoked, or suspended, or why 2 the renewal should not be refused. The order to show cause 3 shall contain a statement of the basis therefor and shall call 4 upon the applicant or registrant to appear before the department 5 of public safety at a time and place not less than thirty days 6 after the date of service of the order, but in the case of a 7 denial or renewal of registration the show cause order shall be 8 served not later than thirty days before the expiration of the 9 registration. These proceedings shall be conducted in 10 accordance with chapter 91 without regard to any criminal 11 prosecution or other proceeding. Proceedings to refuse renewal 12 of registration shall not abate the existing registration which **13** shall remain in effect pending the outcome of the administrative 14 hearing.] If, upon examination of the application for 15 registration from any applicant and other information gathered 16 by the department regarding the applicant, the administrator is 17 unable to make the determinations required by the applicable **18** provisions of sections 329-32 and 329-33 and applicable rules to 19 register the applicant, the administrator shall serve upon the 20 applicant an order to show cause why the registration should not 21 be denied.

| 1  | (b) If, upon information gathered by the department              |
|----|--|
| 2  | regarding any registrant, the administrator determines that the  |
| 3  | registration of such registrant is subject to suspension or      |
| 4  | revocation pursuant to section 329-34 or applicable rules, the   |
| 5  | department shall serve upon the registrant an order to show      |
| 6  | cause why the registration should not be revoked or suspended.   |
| 7  | (c) The order to show cause shall call upon the applicant        |
| 8  | or registrant to appear before the department at a time and      |
| 9  | place stated in the order, which shall be not less than thirty   |
| 10 | days after the date of receipt of the order. The order to show   |
| 11 | cause shall also contain a statement of the legal basis for such |
| 12 | hearing and for the denial, revocation, or suspension of         |
| 13 | registration, and a summary of the matters of fact and law       |
| 14 | asserted.  |
| 15 | (d) Upon receipt of an order to show cause, the applicant        |
| 16 | or registrant shall, if the registrant or applicant desires a    |
| 17 | hearing, file a request for a hearing with the department within |
| 18 | thirty days after service of the order to show cause. Failure    |
| 19 | to request a hearing shall result in the automatic termination   |
| 20 | of the registrant's registration and in the case of a new        |
| 21 | application or renewal, the unprocessed application shall be     |
| 22 | returned to the applicant.                                       |



## H.B. NO. 2592

1 [<del>(b)</del>] (e) The department of public safety may suspend any 2 registration simultaneously with the institution of proceedings 3 under section 329-34, or where renewal of registration is 4 refused, if it finds that there is an imminent danger to the 5 public health or safety which warrants this action. 6 suspension shall continue in effect until the conclusion of the 7 proceedings, including judicial review thereof, unless sooner 8 withdrawn by the department of public safety or dissolved by a 9 court of competent jurisdiction. 10 [<del>(c)</del>] (f) The department of public safety may subpoena and 11 examine witnesses under oath upon all such charges as may be **12** [preferred] referred before it[, and the circuit court of the **13** circuit in which the hearing is held shall enforce by 14 appropriate order the attendance and testimony of witnesses so 15 subpoenaed]." 16 SECTION 6. Section 329-64, Hawaii Revised Statutes, is **17** amended by amending subsection (a) to read as follows: 18 The requirements imposed by sections 329-62[7] and 19 329-63(a) [, and 329-67] of this part shall not apply to any of

the following:

20

| •  | ( - )          | Mily pharmacist of other authorized person who seris or     |
|----|----------------|---|
| 2  |                | furnishes a substance upon the prescription of a            |
| 3  |                | physician, dentist, podiatrist, or veterinarian;            |
| 4  | (2)            | Any physician, dentist, podiatrist, or veterinarian         |
| 5  | ,              | who administers or furnishes a substance to patients;       |
| 6  | (3)            | Any manufacturer or wholesaler licensed by the State        |
| 7  |                | who sells, transfers, or otherwise furnishes a              |
| 8  |                | substance to a licensed pharmacy, physician, dentist,       |
| 9  |                | podiatrist, or veterinarian;                                |
| 10 | (4)            | Any sale, transfer, furnishing, or receipt of any drug      |
| 11 |                | that contains pseudoephedrine or norpseudoephedrine         |
| 12 |                | that is lawfully sold, transferred, or furnished over       |
| 13 |                | the counter without a prescription pursuant to the          |
| 14 |                | federal Food, Drug, and Cosmetic Act (21 United States      |
| 15 |                | Code Sec. 301 et seq.) or regulations adopted               |
| 16 |                | thereunder as long as it complies with the                  |
| 17 |                | requirements of sections 329-73, 329-74, and 329-75[ $_{7}$ |
| 18 |                | and   |
| 19 | <del>(5)</del> | Any "dietary supplement" as defined by the federal          |
| 20 |                | Food, Drug, and Cosmetic Act (21 United States Code         |
| 21 |                | Sec. 301) containing ephedrine alkaloids extracted          |

| 1         | £x             | <del>:om-an</del> | y species of Ephedra that meets all of the              |
|-----------|----------------|-------------------|---|
| 2         | £e             | <del>)llowi</del> | n <del>g criteria:</del>                                |
| <b>'3</b> | <del>(</del> A | <del>.)</del>     | contains, per dosage unit or serving, not more          |
| 4         |                | ŧh                | an twenty five-milligrams of ephedrine                  |
| 5         |                | al                | <del>caloids and its labeling does not suggest or</del> |
| 6         |                | re                | commend a total daily intake of more than one           |
| 7         |                | <del>hu</del>     | adred milligrams of ephedrine alkaloids;                |
| 8         | <del>(B</del>  | <del>))</del> It  | contains no hydrochloride or sulfate salts of           |
| 9         |                | <del>ep</del>     | nedrine-alkaloids; and                                  |
| 10        | <del>(</del> C | <del>!) It</del>  | is packaged with a prominent label securely             |
| 11        |                | a£                | Fixed to each package that states all of the            |
| 12        |                | €o                | llowing:  |
| 13        |                | <del>(i</del>     | The amount in milligrams of ephedrine                   |
| 14        |                |                   | alkaloids in a dosage unit or serving;                  |
| 15        |                | <del>(ii</del> )  | The amount of the dietary supplement that               |
| 16        |                |                   | constitutes a dosage unit-or serving; and               |
| 17        |                | <del>(iii</del> ) | The maximum-recommended-dosage of ephedrine             |
| 18        |                |                   | alkaloids for a healthy adult human is not              |
| 19        |                |                   | more-than one hundred milligrams in a                   |
| 20        |                |                   | twenty four hour period]."                              |
| 21        | SECTION        | . <b>7.</b>       | Section 329-101, Hawaii Revised Statutes, is            |
| 22        | amended by a   | .mendi:           | ng subsection (f) to read as follows:                   |

- 1 "(f) Intentional or knowing failure to transmit any
- 2 information as required by this section, including requests by
- 3 the designated state agency for data corrections, shall be a
- 4 misdemeanor, may incur administrative fines, and shall result in
- 5 the immediate suspension of that pharmacy or practitioner's
- 6 ability to dispense controlled [4] substances[4] in the [State]
- 7 state until authorized by the administrator."
- 8 SECTION 8. Section 329-104, Hawaii Revised Statutes, is
- 9 amended to read as follows:
- 10 "§329-104 Confidentiality of information; disclosure of
- 11 information. (a) The information collected under this part
- 12 shall not be available to the public or used for any commercial
- 13 purpose. Ownership of all data collected shall reside with the
- 14 State.
- 15 (b) Responsibility for limiting access to information in
- 16 the system is vested in the administrator. Access to the
- 17 information collected at the central repository pursuant to this
- 18 part shall be confidential, and access to the information shall
- 19 be limited to [+
- 20 (1) Personnel personnel of the designated state agency [7
- 21 and

| 1  | <del>(2)</del> | The Drug Enforcement Administration diversion group    |
|----|----------------|--|
| 2  |                | supervisor].   |
| 3  | (c)            | This section shall not prevent the disclosure, at the  |
| 4  | discretio      | on of the administrator, of investigative information  |
| 5  | to:            |  |
| 6  | (1)            | Law enforcement officers, investigative agents of      |
| 7  |                | federal, state, or county law enforcement agencies,    |
| 8  |                | United States attorneys, county prosecuting attorneys, |
| 9  |                | or the attorney general; provided that the             |
| 10 |                | administrator has reasonable grounds to believe that   |
| 11 |                | the disclosure of any information collected under this |
| 12 |                | part is in furtherance of an ongoing criminal or       |
| 13 |                | regulatory investigation or prosecution;               |
| 14 | (2)            | Registrants authorized under chapters 448, 453, and    |
| 15 |                | 463E who are registered to administer, prescribe, or   |
| 16 |                | dispense controlled substances; provided that the      |
| 17 |                | information disclosed relates only to the registrant's |
| 18 |                | own patient;   |
| 19 | (3)            | Pharmacists, employed by a pharmacy registered under   |
| 20 |                | section 329-32, who request prescription information   |
| 21 |                | about a customer relating to a violation or possible   |
| 22 |                | violation of this chapter; or                          |

- 1 (4) Other state-authorized governmental prescription-
- 2 monitoring programs.
- 3 Information disclosed to a registrant, pharmacist, or authorized
- 4 government agency under this section shall be transmitted by a
- 5 secure means determined by the designated agency.
- 6 (d) No person shall knowingly disclose or attempt to
- 7 disclose, or use or attempt to use, information in the system in
- 8 violation of this section. Any person who violates this section
- 9 is guilty of a class C felony.
- 10 [(e) The designated state agency shall purge or cause to
- 11 be purged from the central repository system, no later than
- 12 three years after the date a patient's prescription data are
- 13 made available to the designated state agency, the
- 14 identification number of the patient, unless the information is
- 15 part of an active investigation.]"
- 16 SECTION 9. Statutory material to be repealed is bracketed
- 17 and stricken. New statutory material is underscored.
- 18 SECTION 10. This Act shall take effect upon its approval.

### Report Title:

Controlled Substances

### Description:

Makes Hawaii's controlled substance laws consistent with that of federal law, and clarifies sections of chapter 329 relating to controlled substances. (HB2592 HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.